ate-induced seizures (1) (2) (3) (4) . In humans, two genes have been characterized encoding proteins that exhibit a high degree of homology with CaMKLK. KIAA0369 encodes a 740-amino acidlong protein (5) of which the C-terminal 400 amino acids are 99% identical to CaMKLK, suggesting that the KIAA0369 gene is the human analogue of rat CaMKLK. The N-terminal 300 amino acids of KIAA0369 exhibit 70% sequence identity with a protein predicted by the human doublecortin (DC) gene; the noncatalytic N terminus of rat CaMKLK also has 70% sequence identity with the C-terminal amino acids of human DC (3) . Mutations in the DC gene have been associated with the double cortex syndrome, a disease that is characterized by a malformation of the cortex and by mental retardation and epileptic attacks (6, 7) .
Possible functions of CaMKLK are indicated by several reports describing that modulation of the Ca 2ϩ /calmodulindependent protein kinase (CaMK) signaling pathway is associated with neuronal survival or neuronal apoptosis. For example, Akt/PKB, an anti-apoptotic kinase that inactivates proapoptotic Bax, is activated by CaMK kinase, thus linking the CaMK cascade to pathways mediating neuronal survival (8) . Inhibition of CaMK-II activity with CaMK-specific inhibitors induces apoptosis in NIH 3T3 cells (9) and sensitizes etoposide-resistant cells to apoptotic challenge (10) . In particular, CaMK-IV, a downstream effector molecule of CaMK kinase, has been associated with apoptosis. Thymic T cells from transgenic mice expressing a catalytically inactive form of CaMK-IV show defects in survival and activation (11) . Moreover, CaMK-IV is cleaved during apoptosis in SH-SY5Y cells challenged with the proapoptotic agent thapsigargin, suggesting that CaMK-IV is a survival signal, which needs to be shut off during cell death (12) .
A key factor in apoptosis is the activation of caspases, cysteine proteases that cleave a variety of proteins and by doing so disable important cellular processes and break down structural components such as laminin, eventually causing apoptotic cell death (13) . In adult neurons, caspase family members, in particular caspase-3 (14) , are the critical effectors of neuronal death. This has been demonstrated in a variety of in vitro models, such as PC12 cells (15) , primary cervical ganglia neurons (16) , and primary cerebral granule neurons (17) . In addition, activation of caspases, although not always accompanied by overt apoptosis, has been shown to be associated with a number of acute and chronic neurodegenerative brain disorders (reviewed in Refs. 18 and 19) such as ischemia and Alzheimer's disease. The importance of caspase activation for neuronal cell death is underscored by studies showing that the broad spectrum caspase inhibitor ZVAD.fmk exerts significant neuroprotection in mouse models of transient cerebral ischemia (20 -22) .
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¶ To whom correspondence should be addressed: Medical Pharmacology/LACDR, P.O. Box 9503, 2300 RA Leiden, The Netherlands. 59 -62 that is a potential caspase cleavage site (13) . This, in combination with the fact that a CaMKLK splice variant is up-regulated during kainate-induced seizures, a process accompanied by apoptosis (23) , prompted us to investigate the role of the CaMKLK gene in apoptosis. We found that it is a substrate for caspases and that overexpression of a noncleavable mutant protects NG108 cells from serum-deprived apoptosis, while overexpression of a caspase-generated serine/proline-rich N-terminal CaMKLK fragment exacerbates apoptosis. Together, our data suggest that cleavage of CAMKLK facilitates neuronal apoptosis.
EXPERIMENTAL PROCEDURES
Reagents and Antibodies-Anti-CaMKLK antibodies were produced in rabbits by injection of a 55-amino acid-long synthetic peptide immunogen corresponding to the N-terminal domain of CaMKLK, designated CARP (3) . Western blot analysis of synthetic CARP and cell lysates of transfected and nontransfected COS cells shows that the anti-CARP antibody recognizes both CARP and full-length CaMKLK (data not shown). Anti-CaMK-IV antibody (polyclonal) was obtained from Santa Cruz Biotechnology, Inc.; anti-cytochrome C for immunoblotting, clone 7H8.2C12, FITC-conjugated annexin-V, and propidium iodide (PI) were from Pharmingen (San Diego, CA); and anti-FLAG antibody (M2) was from Sigma. Horseradish peroxidase-conjugated secondary antibodies were from Amersham Pharmacia Biotech, and FITCconjugated secondary antibodies were from Molecular Probes, Inc. (Eugene, OR). ZVAD.fmk, DEVD.fmk, human recombinant caspase-3, and caspase-8 were obtained from Calbiochem. All other chemicals were obtained from Sigma.
Cell Culture and Treatment-All cell culture chemicals were obtained from Life Technologies, Inc. NG108-15 cells were obtained from the ATCC (Manassas, VA) and maintained at 37°C, 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM) without sodium pyruvate (catalog no. 11965), supplemented with 100 units/ml penicillin, 100 g/ml streptomycin, hybridoma (HAT) mix, and 10% fetal calf serum. At t ϭ 0, cells grown to 80% confluence were washed three times with DMEM (37°C) and exposed to 2 M thapsigargin (from a 20 mM stock solution in Me 2 SO), 20 -200 nM staurosporine (from a 0.2 mM stock solution in Me 2 SO), and 2 mM EGTA in DMEM, supplemented with 0.1% serum for the indicated times. When needed, cells were preincubated with inhibitors for 30 min prior to the addition of the above mentioned chemicals. Transient transfection experiments were performed with Superfect (Qiagen, Valencia, CA) according to the protocol of the manufacturer. Cells were exposed to staurosporine 24 h after transfection, and the viability was assessed based on morphology by microscopy.
Immunnocytochemistry and Hoechst Staining of Nuclei-Cells were cultured on eight-well Lab-Tek R chamberslides (Nunc, Naperville, IL) and treated as described above. At the indicated times, cells were fixed with 3.7% paraformaldehyde in phosphate-buffered saline (PBS) for 30 min at room temperature. Cells were rinsed three times with PBS and blocked for at least 1 h with blocking buffer: PBS, pH 7.2, 0.1% immunoglobulin-free bovine serum albumin, 0.5% Triton X-100. Cells were incubated overnight at 4°C with primary antibody in blocking buffer, washed three times with PBS, incubated with FITC-conjugated secondary antibody in blocking buffer with or without 0.1 g/ml Hoechst 33342 for 3 h, rinsed three times with PBS, and analyzed. Images were obtained with a Zeiss inverted fluorescent microscope (Axiovert S100 TV) coupled to a Hamamatsu digital camera (C4742-95) operated by Openlab 2.2.0 software (Becton Dickinson).
Flow Cytometry-The percentage of live, dead, and apoptotic cells was determined using FITC-conjugated annexin-V and PI (Pharmingen).
Cells were trypsinized, washed twice with ice-cold PBS, and resuspended in binding buffer (10 mM Hepes/NaOH, pH 7.4, 145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2.5 mM CaCl 2 ) at 1 ϫ 10 6 cells/ml. Five l of the annexin solution and 10 l of 1 mM PI were then added to 100 l of cell suspension. Cells were incubated in the dark for at least 15 min and analyzed using a FACscan flow cytometer (Becton Dickinson), equipped with an argon laser, using the Lysis II program. FITC fluorescence was detected in the FL 1 detector (emission 500 -550 nm; green). PI fluorescence was detected by the FL 3 detector (emission Ͼ600 nm; red). Apoptotic cells were defined as annexin-V-positive/PI negative cells. Necrotic cells were annexin-V-and PI-positive cells. Viable cells were both PI-and annexin-V-negative.
Protein Extraction and Western Blotting-Total protein was extracted by lysing a million cells in 100 l of lysis buffer (50 mM Tris-Cl, pH 8.0, 150 mM NaCl, 1% Triton, supplemented with Complete TM EDTA-free protease inhibitor mixture (Roche Molecular Biochemicals). Protein concentration was determined with a modified Lowry assay (Bio-Rad Dc protein assay kit). Equal amounts of protein were separated by electrophoresis on an SDS-polyacrylamide gel (10 -15%) and semidry electroblotted to a polyvinylidene difluoride membrane, Immobilon-P (Millipore Corp., Bedford, MA).
Blots were blocked with blocking buffer (Tris-buffered saline, 0.2% Tween (TBS-T), 2.5% milk) and incubated with primary antibodies overnight at 4°C in blocking buffer, washed three times with blocking buffer, incubated with secondary HPA-conjugated antibodies for 3 h at room temperature, and washed three times. Binding was detected by enhanced chemiluminescence.
DNA Constructs-All CaMKLK cDNA templates were derived from the plasmids described by Vreugdenhil et al. (3) and subcloned in the expression vector pcDNA3.1 (InVitrogen, Groningen, The Netherlands). The C-terminal FLAG-tagged wild type CaMKLK was constructed by PCR-amplifying a 1.3-kilobase pair fragment using the sense oligonucleotide CCAGGATCCACCATGTTAGAACTCATAG and antisense oligonucleotide CCCGAATTCCTACTTGTCATCGTCGTCCTTGTAGTCA-AAGGGCGAATTGGGGGAG and PfuI as a proofreading polymerase.
After purification on QuiaQuick columns, the fragment was digested with BamHI and EcoRI (underlined in oligonucleotides) and subcloned into the corresponding sites of pcDNA3.1.
Similarly, the C-terminal CaMKLK construct was synthesized using CCAGGATCCACCATGGGCCCTGGGGAAGAAGAGTC as a sense oligonucleotide and CCCGAATTCCTACTTGTCATCGTCGTCCTTGTAG-TCAAAGGGCGAATTGGGGGAG as antisense oligonucleotide.
The N-terminal CaMKLK construct was generated by using CCAG-GATCCACCATGTTAGAACTCATAG as a sense oligonucleotide and CGCGAATTCCTAATCGTTCTCATCCATTGAGCTGCA as an antisense primer.
Finally, an Asp 62 3 Asn CaMKLK mutant was synthesized using CAATGGATGAGAACAATGGCCCTGGGGAAG as a sense and CTTC-CCCAGGGCCATTGTTCTCATCCATTG as an antisense oligonucleotide in the QuickChange site-directed mutagenesis kit (Stratagene, La Jolla, CA) according to the instructions of the manufacturer.
RT-PCR Detection of CaMKLK-Total RNA was isolated from NG108 cells using Trizol, according to the manufacturer's instructions. As a negative control, serum without any NG108 cells was used and processed similarly. Five g of total RNA was reverse transcribed into cDNA with Superscript II (Life Technologies, Inc.) according to the accompanying instructions at 42°C for 1 h with oligo(dT) as primer. The cDNA was diluted to 200 l and 5 l of this was used as a template in a subsequent PCR with AGCTCTCTACTCCACGCTCG as sense primer and GGCCCATCAAGATCTGGTCA as antisense primer at 1 pmol each, 125 mmol of dNTPs, 1 unit of Supertaq (SphearoQ, Leiden, The Netherlands) and 1ϫ Supertaq buffer. PCR conditions were 4 min at 95°C, followed by 27 cycles at 48°C for 1 min, 72°C for 1 min, and 95°C for 30 s.
Kinase Assays-NG108 cells were transfected in triplicate with Superfect transfection reagent (Qiagen) according to the protocol of the manufacturer and lysed after 24 h in lysis buffer (50 mM ␤-glycerophosphate, pH 7.2, 1.5 mM DTT, 1 mM Na 3 VO 4 , 5 mM NaFl) and protease inhibitors. The cells were scraped from the plate and centrifuged (14,000 ϫ g, 30 min, 4°C); supernatant was collected, and protein concentration was determined using the Pierce method. 0.5 mg of protein was incubated with an anti-FLAG M2 monoclonal antibody (Sigma) for 3 h at 4°C and then precipitated with protein G-Sepharose. The precipitate was washed three times with 0.1% Nonidet P-40 in PBS, once with 0.5 M LiCl in PBS, and twice in washing buffer (15 mM ␤-glycerophosphate, pH 7.2, 0.75 mM EGTA, 0.5 mM EDTA, 0.5 mM DTT, 0.5 mM Na 3 VO 4 ).
Washed immunoprecipitates were aspirated to 30 l, and 10 l of this was added to 10 l of buffer B (125 mM Hepes, pH 7.5, 25 mM MgAc, 125 mM ␤-glycerophosphate, pH 7.2, 2.5 mM Na 3 VO 4 , 3 Ci of [␥-
32 P]ATP, and 1.25 mM ATP), 15 l of myelin basic protein (1 g/l) and incubated at 30°C for 30 min. Reactions were stopped by adding 15 l of loading buffer (200 mM Tris, pH 6.8, 30% glycerol, 9% SDS, 2.5% ␤-mercaptoethanol, and 20% saturated solution of bromphenol blue in water) and heating for 5 min at 100°C. Subsequently, samples were size-separated on 12.5% polyacrylamide-SDS gels (20 h, 75 V), which were dried and exposed to x-ray film. The density of bands was determined using NIH Image 1.62 software. Values were corrected for background and for the amount of immunoprecipitated antigen. The latter was determined by Western blot analysis of the immunoprecipitated material using the polyclonal antibody FLAG probe CD8 in combination with the ECL kit (Amersham Pharmacia Biotech).
Microinjection Experiments-Cells were seeded on glass-bottomed coverslip dishes (Matteck Corp., Ashland, OR) 24 -48 h prior to injection. Nuclear microinjection was performed using an automated microinjection system (Eppendorf Transjector 5246, micromanipulator 5171). Identical standardized conditions of pressure (150 hectopascals) and time (0.1 s) were used for microinjection in all experiments.
CaMKLK plasmid DNA was mixed 1:5 with EGFP-N1 reporter plasmid (CLONTECH, Palo Alto, CA) in ultrapure water to a final concentration of 100 ng/l of CaMKLK plasmid. Cells were injected, and the next morning the number of green viable cells was counted (t ϭ 0). Cells were washed three times with serum-free medium to remove all serum and kept in serum-free medium. Cells were counted again 48 h after serum withdrawal. Viability was expressed as green viable cells at a given time after serum withdrawal as percentage of green cells at t ϭ 0. For each construct, at least 400 green cells were counted from an average of six independent injection experiments. Injection of pcDNA 3.1 plasmid served as control.
In Vitro Translation and Degradation of CaMKLK-CaMKLK was in vitro translated using rabbit reticulocyte lysate (TNT transcription/ translation system) in a 50-l reaction volume with 35 S-labeled methionine (Redivue; Amersham Pharmacia Biotech) according to the manufacturer (Promega, Madison, WI).
Five l of the in vitro translation reaction were used in a 50-l caspase degradation assay with 40 units of recombinant caspase. Reactions were incubated for 3 h at 37°C and stopped by the addition of loading buffer and boiling for 5 min. Samples were separated on 10% SDS-polyacrylamide gel electrophoresis. The gel was fixed for 15 min in destain solution, dried at 80°C for 1 h, and exposed overnight to Kodak Biomax film.
Caspase-3 assay conditions were as follows: 100 mM Hepes, pH 7.0, 20% glycerol, 5 mM DTT, and 0.5 mM EDTA. Caspase-8 assay conditions were as follows: 100 mM PIPES, pH 7.2, 500 mM NaCl, 5 mM EDTA, 0.5% CHAPS, 50% sucrose, 50 mM DTT (24) . Caspases were preincubated with 50 M ZVAD.fmk 30 min prior to the addition of the in vitro translated CaMKLK.
Biochemical Techniques-Subcellular fractionation was performed as described in Ref. 25 . Cells grown on 15-cm dishes were scraped using a Teflon scraper, collected by centrifugation at 2,000 ϫ g, and washed twice with PBS. Cells were resuspended in sucrose-supplemented cell extract buffer (SCEB; 300 mM sucrose, 10 mM HEPES, pH 7.4, 50 mM KCl, 5 mM EGTA, 5 mM MgCl 2 , 1 mM DTT, 10 M cytochalasin B, 1 mM phenylmethylsulfonyl fluoride), left on ice for 30 min, and then homogenized by 50 strokes in an ice-cold Dounce homogenizer. Intact cells and nuclei were pelleted by centrifugation for 10 min at 2,000 ϫ g. Mitochondria were collected from the resulting supernatant by centrifugation at 13,000 ϫ g for 10 min. The mitochondrial pellet, resuspended in SCEB and the postmitochondrial fraction, was aliquotted and frozen at Ϫ80°C prior to protein determination and immunoblotting.
For immunoblotting, 10 g of mitochondrial and 20 g of postmitochondrial fractions were separated on SDS-polyacrylamide gel electrophoresis and electroblotted onto Immobilon-P.
RESULTS

CaMKLK Is Expressed in NG108-15 Cells-To determine whether the novel kinase CaMKLK is expressed in NG108-15 cells, we performed Western blot analysis and RT-PCR experiments.
A synthetic peptide immunogen, corresponding to the serine/proline-rich N terminus of CaMKLK, was used to raise polyclonal antibodies. This region is similar to the serine/proline-rich region of CaMK-IV. In order to rule out the possibility of cross-reactivity, blots were stained with both anti-CaMKLK (Fig. 1A) and anti-CaMK-IV (Fig. 1B) . The blot incubated with anti-CaMKLK revealed one major band of 52 kDa, which was smaller than the band recognized by the anti-CaMK-IV antibody (Fig. 1B) . In accordance with other studies, the antiCaMK-IV antibody recognized a 62-kDa band.
RT-PCR confirmed CaMKLK expression in NG108-15 cells. Using two CaMKLK-specific primers, a single band was observed of ϳ850 base pairs after 27 rounds of amplification, which is in agreement with an expected CaMKLK cDNA fragment of 851 base pairs (Fig. 2) . We conclude that both CaMKLK transcripts and protein are expressed in NG108 cells, allowing the study of CaMKLK function in these cells as an in vitro model system.
CaMKLK Is a Caspase Substrate in Vitro-To test whether CaMKLK is a substrate for caspases, we incubated radiolabeled CaMKLK with recombinant caspase-8, an early "upstream" caspase, and caspase-3, a presumed effector caspase (13) .
CaMKLK is cleaved by both caspase-8 and -3 (Fig. 3, A and  B) at the same caspase site, generating a detectable and characteristic 42-kDa cleavage product. The size of the caspasegenerated fragment (42 kDa) (lane 2 in Fig. 3A , lane 1 in Fig.  3B ) is identical to the size of an in vitro translated construct starting at the 59 DEND 62 and ending at the C terminus of CaMKLK (C-terminal) protein (Fig. 3, C-term 
CaMKLK Is a Caspase Substrate in NG108-15 Cells
to all agents within 18 h. The observed death was indeed apoptotic, since cells exposed to all agents displayed chromatin condensation and fragmentation typical of apoptosis. An example is shown in Fig. 4 . Cells also released cytochrome c from the mitochondria into the cytosol (Fig. 5) , another hallmark of apoptosis. Finally, cells exposed phosphatidylserine on the exterior of the cells as determined using fluorescence-activated cell sorting analysis of annexin-V staining of live cells (Fig. 6 ).
Next, we investigated possible CaMKLK cleavage during apoptosis. We transfected FLAG-tagged CaMKLK into NG108-15 cells and subsequently induced apoptosis with staurosporine. FLAG-tagged CaMKLK was cleaved by the endogenous caspases in NG108 cells undergoing apoptosis (Fig. 7) . The cleavage probably occurs at the putative caspase site described above, since we observed only a single cleavage product whose size (42 kDa) is identical to that of the fragment generated by incubation of CaMKLK with recombinant caspase-3 and -8 (Fig. 3) .
Overexpression of a Noncleavable Mutant of CaMKLK Reduces Apoptosis-In order to assess whether the cleavage of CaMKLK by caspases serves some facilitating purpose during apoptosis, we determined the effect of expression of a noncleavable mutant Asp 62 3 Asn CaMKLK on staurosporine-induced apoptosis. Bcl-x L , a potent protector of cells undergoing apoptosis, which depends on release of cytochrome c from the mitochondria (26) , was used as a positive control. As expected, compared with the control (pcDNA 3.1; see Fig. 8A ), overexpression of Bcl-x L reduces cell death considerably (Fig. 8D) . All cells transfected with pcDNA 3.1 had detached from the plate within 18 h of staurosporine exposure (Fig. 8A) , whereas 20 -30% of cells transfected with Bcl-x L were still attached after 18 h of exposure to staurosporine. Overexpression of wild type CaMKLK (Fig. 8C) This suggested that the actual cleavage of CaMKLK facilitated apoptosis and indicated that CaMKLK is not just a victim of caspases, activated during apoptosis. In order to assess whether one or both of the generated fragments served possible proapoptotic functions, we studied the effect of the individual cleavage products as well as the noncleavable mutant on apoptosis in NG108 cells in more detail.
The Caspase-generated N-terminal Cleavage Fragment of CaMKLK Harbors Proapoptotic Activity-In order to be able to look simultaneously at both exacerbation and protection of death, NG108-15 cells were subjected to serum deprivation, which results in protracted apoptotic death. We administered plasmids encoding noncleavable CaMKLK, full-length CaMKLK, and the C-and N-terminal caspase-generated fragments by microinjection, in order to identify which part of the CaMKLK molecule might be important for apoptosis to proceed.
Cells were injected with CaMKLK constructs mixed with enhanced green fluorescent protein as described. At t ϭ 0, green viable cells were counted and serum was withdrawn. Injection of empty vector (pcDNA 3.1) served as control. After 48 h, the viability of the control injected cells was 47 Ϯ 5% (Fig.  9, control) .
Microinjection of the noncleavable CaMKLK mutant significantly reduced cell death induced by serum withdrawal after 48 h. Asp 62 3 Asn CaMKLK-injected cells displayed a viability of 69 Ϯ 7%, which is significantly different from control (p ϭ 0.04) (Fig. 9 , Asp 62 3 Asn CaMKLK) in concordance with the protective effect of Asp 62 3 Asn CaMKLK on staurosporineinduced apoptosis described above. Microinjection of full-length CaMKLK or the C-terminal caspase cleavage fragment of CaMKLK had no effect on apoptosis; viability after 48 h of serum deprivation was 48 Ϯ 8 and 47 Ϯ 5% respectively, not significantly different from control. This indicated that the kinase itself, even when overexpressed, is not an inducer of apoptosis. In contrast, cells injected with the N-terminal cleavage product (Fig. 9 , N-Term) exhibited increased cell death; viability at 48 h was 32 Ϯ 6%, which is significantly different from control (p ϭ 0.04). These observations indicate that a proapoptic function is located on the N-terminal part of the CaMKLK protein.
Taken together, the data indicate that a noncleavable CaMKLK reduces apoptosis induced by both serum withdrawal and staurosporine and that a proapoptotic function is located within the N-terminal caspase-generated fragment of CaMKLK.
Kinase Activity Is Not Altered in the Asp 62 3 Asn CaMKLK Mutant-One could argue that the protection by the noncleavable CaMKLK is only due to alteration of the kinase activity as a consequence of the introduced mutation. To address this question, we transfected NG108 cells with the different CaMKLK constructs and determined their CaMKLK kinase activity. Substitution of Asp 62 into Asn 62 of CaMKLK did not result in a significant change in enzymatic activity (Fig. 10) . This indicated that alteration of CaMKLK activity is unlikely to contribute to protection from apoptosis in NG108 cells and thus makes it more plausible that the Asp 62 3 Asn mutant protects from apoptosis because of its inability to be cleaved by caspases. DISCUSSION We have identified a domain in a CaMK family member, CaMKLK, which exhibits proapoptotic properties. similar kinase activity as wild-type CaMKLK, the observed protection is not just caused by a difference in CaMKLK kinase activity of the mutant due to the introduced mutation. Thus, we have identified a novel molecule, which is functionally important in the execution of apoptosis in NG108 cells. In addition, our findings further substantiate a key role of CaMKs in modulation of neuronal apoptosis in general.
CaMK Family Members and Apoptosis-At present, CaMKs have been shown to modulate apoptosis via two putative mechanisms. One is through CaMK-IV, which phosphorylates CREB either directly or indirectly via activation of the MAPK pathway (27, 28) . The second route of CaMK-mediated protection is through CaMK kinase, which has been shown to induce Aktmediated BAD phosphorylation, resulting in its inactivation (8, 29, 30) . The role of other CaMK family members (CaMK-I and II) in modulation of neuronal apoptosis is less clear. For CaMK-II, both pro-and anti-apoptotic functions have been reported (31) (32) (33) (34) .
Our data show the involvement of a new member of the CaMK family in neuronal apoptosis and extend the mechanisms by which modulation of survival signaling is accomplished. Whereas the existing models consisted of caspasemediated shutting down of survival signals, our data identify the caspase-mediated activation of proapoptotic function of the N terminus of CaMKLK.
Cleavage Specificity-Both recombinant caspase-3 and -8 can cleave CaMKLK in vitro and in the neuronal cell line NG108. However, to what extent caspase-8 contributes to CaMKLK cleavage in vivo is unclear. The putative site in CaMKLK is DEND, a classical caspase-3 cleavage site (13) . Mature neurons constitutively express low levels of caspase-2, -6, and -8 compared with other cell types (35) . Moreover, it has been shown that the preponderant active caspases in apoptotic cells are caspase-3 and -6 (36). Taken together, this makes caspase-3 the most plausible candidate effector of CaMKLK cleavage in apoptotic neurons. FIG. 3. CaMKLK is cleaved by both  caspase-8 (A) and caspase-3 (B) . 35 Slabeled CaMKLK (size 52 kDa) was incubated with human recombinant caspases at 37°C overnight, with or without 50 M ZVAD.fmk as described under "Experimental Procedures." Note that caspase cleavage products of CaMKLK (lane 2 in A, lane 1 in B) (42 kDa) are identical in size to the predicted fragment: C-terminal part after DEVD cleavage (lanes 4 -6 in A,  lanes 3 and 4 in B) . Incubation of a noncleavable mutant Asp 62 3 Asn with caspases does not result in cleavage (lanes 7-9 in A, lanes 5 and 6 in B) .
FIG. 4. Chromatin condensation and fragmentation in NG108 cells.
Cells were exposed to 20 -200 nM staurosporine (Stauro) in DMEM, 0.1% serum. After 18 h, cells were fixed and stained with 2 g/ml Hoechst as described. Control nuclei (A) display no condensation, and nuclei exposed to 20 nm (B) and 200 nM staurosporine (C) show fragmentation and condensation. Note that nuclei of cells exposed to thapsigargin and EGTA display similar morphology. Cleavage of members of the CaMK family during apoptosis has been observed before (12, 37) . In SH-SY5Y cells undergoing apoptosis, both caspase-3 and calpain cleave CaMK-IV. Our data suggest that CaMKLK is predominantly cleaved by caspases and not by calpain, since overexpressed FLAG-tagged CaMKLK only gives one specific 42-kDa cleavage product, resulting from cleavage at the caspase-3 consensus site (DEND) during apoptosis of NG108-15 cells. It is of interest to note that CaMKLK is readily cleaved by recombinant calpain in vitro, generating multiple degradation products smaller than 42 kDa (results not shown). Such cleavage does not occur in NG108 cells undergoing apoptosis, suggesting that there is no role for calpains in apoptotic death of NG108 cells. However, our data do not rule out a role of calpain-mediated cleavage of CaMKLK in other in vivo models.
Functional Consequences of Cleavage: C-terminal Fragment Retains Kinase Activity, while N-terminal Fragment Mediates
Apoptosis-Cleavage of CaMKs may be a general mechanism activated during apoptosis, since caspase-mediated cleavage of CaMK-IV has been described in cortical neurons exposed to staurosporine (12) and K ϩ -deprived cerebellar granule neurons (37) . During apoptosis of both types of neurons, CaMK-IV is cleaved within the catalytic domain of the kinase, resulting in a 50% reduction of kinase activity and CREB phosphorylation. It is this loss of kinase activity that is believed to be responsible for the loss of CREB phosphorylation and thus loss of expres- sion of neuroprotective genes. In contrast, CaMKLK is cleaved outside of the catalytic domain, which results in a C-terminal cleavage product that retains kinase activity (Figs. 10 and 11 ). This observation raised the possibility that the kinase activity of CaMKLK is involved in neuronal apoptosis. However, overexpression of the caspase-generated C-terminal catalytic N CaMKLK product did not affect apoptosis of serum-deprived NG108 cells. In contrast, overexpression of the noncatalytic N-terminal domain accelerated apoptosis, suggesting a biological significance for this N-terminal domain in the apoptotic process and marking it as proapoptotic.
Our observation that overexpression of the noncleavable Asp 3 Asn 62 CaMKLK mutant protects from both staurosporineand serum deprivation-induced apoptosis can be interpreted in two ways. The observed protection can either be solely due to the fact that the generation of the proapoptotic N-terminal fragment is inhibited, or it indicates that CaMKLK is directly mediating survival, which can no longer be turned off by caspase degradation. Identification of CaMKLK targets is needed to further address this question.
Possible Actions of the Caspase-generated N-terminal CaMKLK Fragment-Growth factor deprivation leads to apoptosis mediated by the release of cytochrome c from the mitochondria by a proapoptotic member of the Bcl-2 family, such as BAD, BID, or Bim (38 -40) . Released cytochrome c then interacts with Apaf-1 to trigger an ATP-dependent activation of caspase-9 and subsequent activation of effector caspases (41, 42) . The intracellular signaling pathways mediating survival are different for different growth factors (28) but seem to converge in the cytosol at the level of the proapoptotic Bcl-2 family members such as BAD and Bim (8, 29, 30) and in the nucleus at CREB-mediated expression of prosurvival genes (37, 43, 44) . The precise role of the N-terminal CaMKLK fragment is presently unknown, but it may affect the apoptotic program underlying serum deprivation in three ways (see also Fig. 12) .
First, the serine-rich structure of the CaMKLK N-terminal domain is very similar to that of the serine-rich N terminus of CaMK-IV (3), which has been shown to possess an autoinhibitory effect on CaMK-IV activity (45) . CaMK-IV exerts neuroprotective effects through phosphorylation of CREB, resulting in the expression of Bcl-2 (37, 43) . Thus, inhibition of CaMK-IV in combination with lower Akt activity due to serum deprivation will lower the levels of the antiapoptotic Bcl-2 while activating the proapoptotic BAD, increasing the propensity of the mitochondria to release cytochrome c and die by apoptosis.
Second, the N-terminal fragment may exacerbate apoptosis through interference with MAPK signaling pathways. MAPK signaling pathways mediate survival in two ways. MAPK-activated pp90 ribosomal S6 kinase family member Rsk-2 phosphorylates and thus inactivates BAD (28, 46) . In addition, MAPK mediates transcription of prosurvival genes such as Bcl-2, either directly or through CREB phosphorylation. The structure of the caspase-generated N-terminal fragment contains the sequence PTSP, which has been described as a target for p42 MAPK (47) . Indeed, we have observed strong phosphorylation of the CaMKLK N terminus by JNK, 2 suggesting that that exacerbation of apoptosis might be mediated through the caspase-generated N terminus. Thus, both pathways (i.e. inhibition of CaMK-IV or MAPK) result in a reduced level of Bcl-2 and activation of the proapoptotic BAD, accelerating apoptosis. Further studies on the effects of the N-terminal fragment on BAD phosphorylation and CREB-mediated expression of prosurvival genes will show if this is indeed the mechanism by which the N-terminal fragment exerts its proapoptotic effect.
Third, the N-terminal CaMKLK fragment has a high amount of amino acid sequence identity with human doublecortin and human KIAA0369 (3). Recently, it was shown that both doublecortin and KIAA0369 (also called DCAMKL1) interact with and stabilize microtubules (6, 48, 49) . Thus, caspase cleavage of CaMKLK might result in an N-terminal fragment, which interferes with microtubule-doublecortin/KIAA0369 or microtubule-microtubule-associated protein interactions, thereby altering microtubule stability and stimulating the progression of 2 E. Vreugdenhil, unpublished data.
FIG. 9.
Effect of microinjected CaMKLK constructs on neuronal cell death induced by serum withdrawal. Cells were injected with CaMKLK constructs mixed with enhanced green fluorescent protein as described. At t ϭ 0, green viable cells were counted, and serum was withdrawn. Cells were recounted 48 h after serum withdrawal. Viability is expressed as percentage of green cells at t ϭ 0. For each construct, at least 400 cells have been counted in at least four injection series. Injection of empty vector served as control. Cells were injected with CaMKLK, Asp 62 3 Asn CaMKLK, the noncleavable CaMKLK mutant, and the C-and N-terminal caspase-generated cleavage fragments of CaMKLK. The N-terminal cleavage fragment only aggravates cell death, whereas the noncleavable form of CaMKLK reduces cell death after 48 h. *, statistically significant relative to control (t test, p Ͻ 0.05).
FIG. 10.
Kinase activity of CaMKLK, the caspase generated C-terminal fragment and Asp 62 3 Asn CaMKLK. NG108 cells were transfected with the different CaMKLK constructs, which were immunoprecipitated after 24 h. Kinase activity was determined as described under "Experimental Procedures" using myelin basic protein as a substrate. The observed activities of CaMKLK and Asp 62 3 Asn CaMKLK do not differ significantly (t test, p Ͻ 0.05).
the apoptotic process. Recently, it has been shown that in cortical neurons microtubule-targeting drugs induce apoptosis by a mechanism requiring JNK signaling to the nucleus and inhibition of the phosphatidylinositol 3-kinase survival pathway (50) . The impact of the CaMKLK N terminus on both pathways requires further investigation. Overexpression of CAMKLK and mutants thereof in combination with activation of CaMK-IV-or JNK-mediated pathways may reveal possible cross-talk.
Future studies on the role of CaMK family members in neuronal apoptosis will probably lead to the identification of more members with additional physiological roles. Our data show that novel members may use novel mechanisms of modulation, which will be of importance for the design of pharmacological strategies aimed at targeting neuronal apoptosis in neurodegenerative disorders.
In conclusion, we have shown that the novel kinase CaMKLK is cleaved by caspases in vitro and in NG108 cells undergoing apoptosis. Prevention of the cleavage reduced the amount of cell death, indicating that the cleavage was functional for the apoptotic process. The role of CaMKLK in neuronal survival is different from that described previously for CaMK family members. Whereas cleavage of CaMK-IV results in loss of kinase activity, with a concomitant loss of survival signals, cleavage of CaMKLK results in the generation of an active proapoptotic function located on the N terminus of CaMKLK. Since this fragment does not contain any obvious enzymatic activity, it probably exerts its action by modulation of other proteins among which other CaMKs, MAPK, and members of the doublecortin family are possible candidates. FIG. 11 . Schematic representation of CaMKLK with the caspase cleavage site located between the kinase domain and the regulatory N-terminal domain. Caspase cleavage yields a C-terminal fragment (42 kDa) with an intact kinase catalytic domain, whereas the N-terminal cleavage fragment (10 kDa) contains no enzymatic activity. The Nterminal cleavage fragment exacerbates apoptosis (A), whereas mutation of the caspase cleavage site, resulting in a noncleavable CaMKLK, protects neurons from apoptosis (B).
FIG. 12.
Schematic representation of the possible action of CaMKLK in neuronal apoptosis. Serum deprivation will induce a caspase-mediated cleavage of CaMKLK, yielding an N-terminal cleavage fragment, which may exacerbate apoptosis by interaction with CaMK-IV or MAPK or by affecting the stabilization of microtubules. In the presence of growth factors (serum), CaMK-IV phosphorylates CREB, directly or through MAPK, resulting in expression of neuroprotective genes. In addition, MAPK mediates the phosphorylation and thus inactivation of the Bcl-2 family member BAD. Serum deprivation will result in a turn-off of these survival signals, and the N-terminal fragment of CaMKLK, generated by an apoptotic signal, exacerbates this.
